Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1

Abstract

Glucagon is known for its insulin-antagonist effect in the blood glucose homeostasis, while it also reduces vascular resistance. The mechanism of the vasoactive effect of glucagon has not been studied before; thereby we aimed to investigate the mediators involved in the vasodilatation induced by glucagon. The vasoactive effect of glucagon, insulin, and glucagon-like peptide-1 was studied on isolated rat thoracic aortic rings using a wire myograph. To investigate the mechanism of the vasodilatation caused by glucagon, we determined the role of the receptor for glucagon and the receptor for GLP-1, and studied also the effect of various inhibitors of gasotransmitters, inhibitors of reactive oxygen species formation, NADPH oxidase, prostaglandin synthesis, protein kinases, potassium channels, and an inhibitor of the Na⁺/Ca²⁺-exchanger. Glucagon causes dose-dependent relaxation in the rat thoracic aorta, which is as potent as that of insulin but greater than that of GLP-1 (7–36) amide. Vasodilatation by GLP-1 is partially mediated by the glucagon receptor. The vasodilatation due to glucagon evokes via the glucagon-receptor, but also via the receptor for GLP-1, and it is endothelium-independent. Contribution of gasotransmitters, prostaglandins, the NADPH oxidase enzyme, free radicals, potassium channels, and the Na⁺/Ca²⁺-exchanger is also significant. Glucagon causes dose-dependent relaxation of rat thoracic aorta in vitro, via the receptor for glucagon and the receptor for GLP-1, while the vasodilatation evoked by GLP-1 also evolves partially via the receptor for glucagon, thereby, a possible crosstalk between the 2 hormones and receptors could occur.

Key words

aortic rings - glucagon - GLP-1 - vasodilatation

• References

• 1 Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The Glucagon Receptor Family. Pharmacol Rev 2003; 55: 167-194
• 2 Charron MJ, Vuguin PM. Lack of glucagon receptor signaling and its implications beyond glucose homeostasis. J Endocrinol 2015; 224: R123-R130
• 3 Jiang 1 Y, Cypess AM, Muse ED, Wu CR, Unson CG, Merrifield RB, Sakmar TP. Glucagon receptor activates extracellular signal-regulated protein kinase 1/2 via cAMP-dependent protein kinase. Proc Natl AcadSci USA 2001; 98: 10102-10107
• 4 Gagnon G, Regoli D, Rioux F. Studies on the mechanism of action of glucagon in strips of rabbit renal artery. Br J Pharmacol 1980; 69: 389-396
• 5 Tolins JP. Mechanisms of glucagon-induced renal vasodilation: role of prostaglandins and endothelium-derived relaxing factor. J LabClinMed 1992; 120: 941-948
• 6 Richardson PD, Withrington PG. The vasodilator actions of isoprenaline, histamine, prostaglandin E2, glucagon and secretin on the hepatic arterial vascular bed of the dog. Br J Pharmacol 1976; 57: 581-588
• 7 Moir TW, Nayler WG. Coronary Vascular Effects of Glucagon in the Isolated Dog Heart. Circ Res 1970; Vol. XXVI
• 8 Rosic M, Pantovic S, Rosic G, Tomic-LucicA Labudovic T, Zivkovic V, Jakovljevic V. Glucagon effects on ischemic vasodilatation in the isolated rat heart. J Biomed Biotechnol 2010; 231832
• 9 Armstead WM, Kiessling JW, Cines DB, Higazi AA. Glucagon protects against impaired NMDA-mediated cerebrovasodilation and cerebral autoregulation during hypotension after brain injury by activating cAMP protein kinase A and inhibiting upregulation of tPA. J Neurotrauma 2011; 28: 451-457
• 10 Armstead WM, Riley J, Cines DB, Higazi AA. Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension aftertraumatic brain injury through inhibition of ERK and JNK MAPK. Neurol Res 2012; 34: 530-537
• 11 Szijártó IA, Molnár GA, Mikolás E, Fisi V, Laczy B, Gollasch M, Koller A, Wittmann I. Increased insulin-induced relaxation of consecutive arterial segments toward the periphery: Role of vascular oxidative state. Free Radic Res 2014; 48: 749-757
• 12 Zavaritskaya O, Zhuravleva N, Schleifenbaum J, Gloe T, Devermann L, Kluge R, Mladenov M, Frey M, Gagov H, Fésüs G, Gollasch M, Schubert R. Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction. Hypertension 2013; 61: 151-159
• 13 Sélley E, Kun S, Szijártó IA, Laczy B, Kovács T, Fülöp F, Wittmann I, Molnár GA. Exenatide induces aortic vasodilation increasing hydrogensulphide, carbonmonoxide and nitric oxide production. Cardiovasc Diabetol 2014; 13: 69
• 14 Halmai R, Szijártó IA, Fehér E, Fésüs G, Molnár GA, Brasnyó P, Fülöp F, Gollasch M, Koller A, Wittmann I. Cigarette smoke elicits relaxation of renal arteries. Eur J Clin Invest 2011; 41: 195-202
• 15 Livingston JN, Einarsson K, Backman L, Ewerth S, Arner P. Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylylcyclase of non-obese and obesesubjects. J ClinInvest 1985; 75: 397-403
• 16 Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003; 305: 800-811
• 17 Ko EA, Han J, Jung ID, Park WS. Physiologicalroles of K+channels in vascular smooth muscle cells. J Smooth Muscle Res 2008; 44: 65-81
• 18 Iwamoto T, Kita S. Hypertension, Na⁺/Ca²⁺exchanger, and Na⁺, K⁺-ATPase. Kidney Int 2006; 69: 2148-2154
• 19 Kieffer TJ, Heller RS, Unson CG, Weir GC, Habener JF. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 1996; 137: 5119-5125
• 20 Runge S, Wulff BS, Madsen K, Bräuner-Osborne H, Knudsen LB. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligandselectivity. Br J Pharmacol 2003; 138: 787-794
• 21 McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidylpeptidase IV inhibitors: how do they work as new antidiabeticagents?. RegulPept 2005; 128: 159-165
• 22 Sauer N, Reining F, Schulze zur Wiesch C, Burkhardt T, Aberle J. Off-Label Antiobesity Treatment in Patients without Diabetes with GLP-1 Agonists in Clinical Practice. Horm Metab Res 2015; 47: 560-564
• 23 Li XC, Zhuo JL. Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise. Clin Sci 2007; 113: 183-193
• 24 Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving K_ATP and cAMP. Arch Biochem Biophys 2008; 478: 136-142
• 25 Nyström T, Gonon AT, SjöholmA Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 173-177
• 26 Richter G, Feddersen O, Wagner U, Barth P, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993; 265: L374-L381
• 27 Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasulature and increases glucose use in microvasculature and increases glucose use in muscle via nitric oxide-dependent mechanism. Diabetes 2012; 61: 888-896
• 28 Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-likepeptide 1 receptor are mediated through both glucagon-likepeptide 1 receptor–dependent and –independent pathways. Circulation 2008; 117: 2340-2350
• 29 Melançon A, Gagnon V, Milot M, Charest É, Foucher D, Péronnet F, Unson O’Brien CG, Asselin E, Lavoie C. Liver glucagon receptors(GluR): effect of exercise and fasting on binding characteristics, GluR-mRNA, and GluR protein content in rats. Horm Metab Res 2013; 45: 716-721
• 30 Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, HvelplundA Bardram L, Calatayud D, Knudsen LB. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280-1290
• 31 Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW. Glucagon-Like Peptide 1 Decreases Lipotoxicity in Non-Alcoholic Steatophepatitis. J Hepatol 2015; pii: S0168–S8278
• 32 Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K. Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015; 45: 269-278
• 33 Olaywi M, Bhatia T, Anand S, Singhal S. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int 2013; 12: 584-588
• 34 Yamashita K, Sato Y, Oki K, Kishimoto H, Yamauchi K, Aizawa T. Marked improvement of insulin sensitivity without enhancement of GLP-1 and insulin secretion after Roux-en-Y gastric bypass surgery in a mildly obese patient with diabetes. Horm Metab Res 2014; 46: 424-426
• 35 Liu R, Ding X, Wang Y, Wang M, Peng Y. Glucagon-like peptide-1 upregulates visfatin expression in 3T3-L1 adipocytes. Horm Metab Res 2013; 45: 646-651
• 36 Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179
• 37 Lee JH, Ragolia L. AKT phosphorylation is essential for insulin-induced relaxation of rat vascular smooth muscle cells. Am J Physiol Cell Physiol 2006; 291: C1355-C1365
• 38 Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28: 463-491